{"analyses":[{"ciLowerLimit":"4.24","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1144","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"28.01","statisticalMethod":"Exact Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.0","upperLimit":"28.7","value":"20.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"4.9","value":"0.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"48 Weeks","title":"The Percentage of Participants Achieving a Durable Primary Response at Week 48","type":"SECONDARY","unitOfMeasure":"percentage of participants"}